ALK rearrangement has been reported in about 5% of all NSCLC cases, typically in never-smokers and younger patients, diagnosed at advanced stages, and presenting a higher risk of brain metastases [58]. This evidence concerns the gene ALK and non-small cell lung carcinoma.